Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tranzyme Pharma
Tranzyme Pharma's Ghrelin Agonist TZP-101 Shows Potential as a Potent Agent for Cancer Cachexia
November 4th, 2008
Tranzyme Pharma, a biopharmaceutical company engaged in the discovery and clinical development of first-in-class small molecule therapeutics, announced that Dr. Helmut Thomas, Senior Vice President of Research and Preclinical Development will present results of a significant proof-of-concept study in cancer cachexia with its novel ghrelin agonist, TZP-101. The presentation will take place at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland on October 23, 2008. In progressively-cachectic female BALB/c nu/nu mice bearing the aggressively-growing metastatic human G361 melanoma, TZP-101, administered subcutaneously,...
Source: Cancer Weekly (2008-11-04)
|
